Cabiralizumab (FPA 008) 是一种抗CSF1R单克隆抗体 (MAb)。Cabiralizumab 可增强 T 细胞浸润和抗肿瘤 T 细胞免疫反应。Cabiralizumab 抑制破骨细胞的活化并阻止骨质破坏，可用于类风湿性关节炎 (RA) 的研究。Cabiralizumab 可与 Nivolumab (HY-P9903) 结合用于肺癌研究。
| 生物活性 | Cabiralizumab (FPA 008) is an anti-CSF1Rmonoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine withNivolumab(HY-P9903) for lungcancerresearch[1][2]. |
| IC50& Target | |
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
